Pfizer on the Street: Analyst Recommendations after 2Q17
As of July 31, 2017, of the 22 analysts tracking Pfizer, ten recommend a “buy” for the stock, while 11 recommend a “hold,” and one recommends a “sell.”
Healthcare
The latest news in the healthcare sector including biotech and telehealth.
Bristol-Myers Squibb’s 2Q17 Earnings: Opdivo
Bristol-Myers Squibb’s (BMY) blockbuster drug Opdivo reported revenue of $1.2 billion in 2Q17, a 42% rise compared to $840 million in 2Q16.
Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017
Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.
Eli Lilly in 2Q17: Humulin and Endocrine Products
Eli Lilly’’s (LLY) Human Pharmaceuticals segment reported a rise of ~11.0% to ~$5.0 billion for 2Q17 compared to ~$4.6 billion for 2Q16.
Bioverativ Expected to Report Healthy Profit Margins in 2017
Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.
Eli Lilly in 2Q17: Performance of New Products
For 2Q17, Basaglar sales were $86.6 million. Of that, $60.0 million was from sales in the US markets, while $27.0 million was from international sales.
Bioverativ Expected to Report Robust Revenue Growth in 2017
In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.
Bioverativ’s Research Pipeline May Boost Future Revenues
Bioverativ (BIVV) plans to improve compliance rates for hemophilia patients further by launching therapies with lower dosage frequency.
Bioverativ–True North Therapeutics: Stronger Research Pipeline
The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).
Behind Pfizer’s Legacy Established Products Performance in 2017
In 2016, Pfizer’s (PFE) Lipitor reported revenues of ~$1.8 billion, which represented a ~5% YoY (year-over-year) fall.
What Led the Rise in GE’s Healthcare Revenue in 2Q17?
GE’s Healthcare segment remained a top performer in 2Q17. Revenue-wise, this segment remained the third-largest contributor to GE’s total operating revenue of $28.0 billion.
Analysts’ Recommendations for AstraZeneca in 2Q17
Wall Street analysts expect AstraZeneca’s top line to fall ~9.5% to $5.1 billion in 2Q17, compared to $5.6 billion in 2Q16. Its earnings per share are expected to be $0.42 in 2Q17.
Pfizer Sees a Significant Opportunity in This for Revenue Growth
In 2016, Pfizer’s (PFE) biosimilar business reported revenues of ~$319 million, compared with $63 million in 2015.
How Analysts View Public Storage
Analysts have assigned PSA a mean price target of $217.67, which is 4.9% higher than its current price level.
Where Public Storage Stands among Other Major Players
Public Storage has consistently been able to return capital value as well as shareholder returns in the form of dividends and share buybacks.
Inside GlaxoSmithKline’s 2Q17 Earnings Estimates
For 2Q17, analysts estimate that GSK’s revenues will rise ~11.4% to ~7.3 billion pounds, as compared to ~6.5 billion pounds for 2Q16.
Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand
Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.
Public Storage and the Growing US Economy
Public Storage (PSA) is expected to witness a higher cost of debt in 2Q17, mainly due to the Fed’s rate hikes in 2017.
Inside Public Storage’s 2Q17 Battle with Macro Headwinds
Public Storage (PSA) is expected to post flat top-line and bottom-line results in 2Q17.
What’s Really Driving Public Storage’s Expected 2Q17 Upbeat Results
Wall Street expects PSA to report adjusted FFO (funds from operation) of $2.40, compared with $2.54 in 2Q16.
Where Abiomed Plans to Expand Impella CP’s Label
About 40% of patients succumb to heart failure within five years. Abiomed believes that it is reperfusion injuries that cause these problems.
Why Ibrance Could Be Pfizer’s Long-Term Growth Driver
Pfizer (PFE) is extensively conducting clinical trials for the label expansion of Ibrance.
Why Ibrance Could Drive Pfizer’s Revenue Growth
In 2016, Pfizer’s (PFE) Ibrance reported revenues of ~$2.1 billion, compared with $723 million in 2015.
Novartis in 2Q17: Performance of Innovative Medicines
The overall contribution of the Innovative Medicines segment was ~67.6% at $8.28 billion for 2Q17.
Foreign Exchange Impacts Novartis’s Growth in 2Q17
In its earnings release on July 8, 2017, Novartis (NVS) reported flat revenues at constant currencies for 2Q17.
Will Public Storage’s Cost-Reduction Initiatives Drive Higher NOI in 2Q17?
Wall Street analysts expect Public Storage (PSA) to report NOI (net operating income) of $483.7 million for 2Q17.
Johnson & Johnson: Consumer Products in 2Q17
The consumer segment Johnson & Johnson’s (JNJ) consumer segment revenue rose 1.7% to $3.5 billion in 2Q17, compared with $3.4 billion in 2Q16. This rise includes operational growth of 2.3%, which was offset by a 0.6% impact of foreign exchange. Baby care franchise The baby care franchise reported revenue of $494 million in 2Q17, a […]
Why Abiomed Expects to Benefit from Impella in Cardiogenic Shock
On March 23, 2015, the FDA approved Abiomed’s Impella 2.5 heart pump as a temporary ventricular support device.
Will Public Storage Ride High on Top Line in 2Q17?
Wall Street expects Public Storage (PSA) to report revenue of $667.9 million for 2Q17. Its earnings call will be on July 27, 2017.
Johnson & Johnson: Medical Devices in 2Q17
Medical devices segment Johnson & Johnson’s (JNJ) medical devices segment grew ~4.9% to ~$6.7 billion for 2Q17, compared with $6.4 billion in 2Q16. This rise included an operational increase of 5.9%, and was offset by a 1% impact of foreign exchange. Cardiovascular care franchise Cardiovascular care franchise sales rose 11.3% to $523 million for 2Q17. This […]
Behind Abiomed’s Plans to Create a Greater Awareness of Impella
To target patients across communities, Abiomed (ABMD) has been developing a hub-and-spoke model with hospitals.
What Lies Ahead for Public Storage in 2Q17
Analysts expect PSA to report adjusted FFO (funds from operation) of $2.40, compared with $2.54 in 2Q16.
Abiomed Aims to Expand Impella RP’s Penetration Going Forward
In March 2017, Abiomed (ABMD) submitted premarket approval (or PMA) to the FDA for its Impella RP device far ahead of schedule.
Behind the Major Drivers of JNJ’s Medical Device Growth
Johnson & Johnson (JNJ) reported Medical Devices segment sales of ~$6.7 billion in 2Q17, compared with $6.4 billion in 2Q16.
A Look at Teva’s Dominance in the Biosimilar Space
As one of the early entrants in biosimilars, Teva Pharmaceutical Industries (TEVA) has managed to become one of the biggest players in the biosimilar space.
Teva’s Generic Value Chain Differentiates It from Its Peers
In addition to its robust strategy, Teva Pharmaceutical also boasts of an extensive presence across all levels of the value chain for its generics business.
Winning? We Review How Teva Dominates Generic Drug Space
Teva Pharmaceutical Industries plans to take advantage of market dynamics and unmet demand in generic pharmaceuticals by enacting a three-pronged strategy.
How Gilead Dominates the HCV Space
In January 2012, Gilead Sciences (GILD) acquired Pharmasset and got access to sofosbuvir. In December 2013, the FDA approved sofosbuvir under the brand name Sovaldi.
The Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics
On September 16, 2016, Johnson & Johnson announced the acquisition of Abbott Medical Optics, a subsidiary of Abbott Laboratories, and its stock fell ~0.3%.
Why REITs Tend to Offer High Dividend Yields
REITs (IYR)(VNQ) are known for their high dividend yields, outclassing almost all other broad market indices.
Will Sanofi See More Growth from Its Blockbuster Insulin Drug?
Sanofi’s diabetes franchise includes Lantus, Toujeo, Amaryl, and Apidra. Lantus, a glargine insulin, contributed 17% of total revenues in fiscal 2015.
GlaxoSmithKline Giving a Shot to Its Vaccines Business
GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired Novartis’s (NVS) meningitis and other vaccines business.
GlaxoSmithKline’s Combo Treatment for HIV Faces Stiff Competition
GlaxoSmithKline’s (GSK) HIV medicines business is managed by ViiV Healthcare, a global specialist company in HIV medicines.
Pfizer’s Hospira Deal: Catching Up a Year Later
On September 13, 2015, Pfizer (PFE) completed its acquisition of Hospira for $17 billion.
Why Did Valspar’s Coatings Segment Revenue Fall in 3Q16?
Valspar (VAL) reports its revenue under two segments, namely: the coatings segment and paints segment.
Market Cheers FDA’s Fast Tracking of BIIB’s Alzheimer’s Treatment
The U.S. Food and Drug Administration (or FDA) recently awarded the fast track status to aducanumab following the positive results of Biogen’s pre-clinical research.
Apache Announces a New Oil and Gas Discovery
On September 7, 2016, Apache (APA) announced a new resource play, Alpine High, in the Delaware Basin of Texas.
Pfizer’s Essential Health Business: What You Need to Know
In this series, we’ll discuss in detail how Pfizer plans to revive growth for the falling Essential Health business.
Why Is Sanofi Expanding in the CHC Space?
Sanofi (SNY) plans to become a leading company in the CHC business. The asset swap will exclude Boehringer Ingelheim’s CHC business in China.
Where Is the Market Headed: Double Bottom? Triple Top?
Double bottom? From a technical standpoint, the current environment may have been viewed as either bullish or bearish. Those on the bull side of the equation took heart in a technical indicator known as the double bottom. The double bottom reversal is a bullish reversal pattern that traders use to anticipate possible upside movements. As its […]